nach oben

Clinical and Translational Oncology

Erschienen in:

01.03.2015 | Research Article

RETRACTED ARTICLE: Profiling of differentially expressed microRNAs (miRNAs) during differentiation of rat hepatic oval cells (HOCs) into hepatocellular carcinoma (HCC) cells

verfasst von: R. H. Xu, L. Y. Zheng, D. L. He, J. Meng, L. P. Xia, X. B. Hao, Z. Z. Zhang

Erschienen in: Clinical and Translational Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

To explore the expression profile of miRNAs during differentiation of rat hepatic oval cells (HOCs) into hepatocellular carcinoma cells (HCC).

Methods

Proliferation of rat HOCs was induced by chemical carcinogen, 3′-methyl-4-dimethylaminoazobenzene (3′-Me-DAB) in male rats. By using Percoll density gradient centrifugation method, HOCs were isolated, followed by continuous cultivation in vitro. The isolated HOCs were identified via Thy-1 and C-kit detection under laser scanning confocal microscope. Total miRNA was then extracted from HOCs during cell differentiation for microarray hybridization. Differentially expressed miRNAs among the indicated time points were identified. The target genes of identified miRNAs were predicted using PicTar, Target-Scan, and miRanda; then the functions and pathways of the genes were enriched. Y chromosome-specific polymerase chain reaction (PCR) technique was utilized to trace the differentiation of the male HOCs in carcinogen-induced HCC of female rats.

Results

It was shown that isolated HOCs expressed stem cells markers of Thy-1 and C-kit in cytoplasm and membrane. Among 1,210 miRNAs identified, 22 were differentially expressed (P < 0.05, fold change ≥2), including 19 up-regulated and 3 down-regulated ones. The predicted target genes of these miRNAs were enriched in several functions, including axon guidance, angiogenesis, post-transcriptional protein modification, and small molecular metabolism. For PCR-based SRY detection, HCC genomic DNA of female rats from the experimental group displayed the same PCR product as that from normal male rat.

Conclusion

Differentially expressed miRNAs exerted important roles during the differentiation process of HOCs to HCC.

Khare S, Zhang Q, Ibdah JA. Epigenetics of hepatocellular carcinoma: role of microRNA. World J Gastroenterol. 2013;19(33):5439.PubMedCentralCrossRefPubMed

Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793–801.CrossRefPubMed

Shi Y, Liu C, Liu X, Tang DG, Wang J. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS One. 2014;9(3):e90022.PubMedCentralCrossRefPubMed

Özata DM, Xie H, Lindforss U, Olivecrona H, Lui W-O. miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol. 2011;39:311–8.

Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol. 2012;44(12):2144–51.PubMedCentralCrossRefPubMed

Xing F, Wu K, Watabe K. MicroRNAs in cancer stem cells: new regulators of stemness. Curr Pharm Des. 2014;28:28.

Nagel R, le Sage C, Diosdado B, van der Waal M, Vrielink JAO, Bolijn A, et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008;68(14):5795–802.CrossRefPubMed

Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007;315(5818):1576–9.PubMedCentralCrossRefPubMed

Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007;21(9):1025–30.PubMedCentralCrossRefPubMed

10.

Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–23.CrossRefPubMed

11.

Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4(8):e6816.PubMedCentralCrossRefPubMed

12.

Wong R, Frenette C. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol. 2011;7(1):16.

13.

Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, et al. Liver stem cells and hepatocellular carcinoma. Hepatology. 2009;49(1):318–29.PubMedCentralCrossRefPubMed

14.

Sell S. On the stem cell origin of cancer. Am J Pathol. 2010;176(6):2584–94.PubMedCentralCrossRefPubMed

15.

Dumble ML, Croager EJ, Yeoh GC, Quail EA. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis. 2002;23(3):435–45.CrossRefPubMed

16.

Grozdanov PN, Yovchev MI, Dabeva MD. The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest. 2006;86(12):1272–84.CrossRefPubMed

17.

Sirica AE, Cihla HP. Isolation and partial characterizations of oval and hyperplastic bile ductular cell-enriched populations from the livers of carcinogen and noncarcinogen-treated rats. Cancer Res. 1984;44(8):3454–66.PubMed

18.

Sinclair A, Berta P, Palmer M, Hawkins J, Griffiths B, Palmer M. A gene from the human sex-determining region encodes a protein with. Nature. 1990;346(6281):240–4.CrossRefPubMed

19.

Eisenreich A, Leppert U. The impact of microRNAs on the regulation of tissue factor biology. Trends Cardiovasc Med. 2013;24(3):129–32.

20.

Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–79.CrossRefPubMed

21.

DeSano JT, Xu L. MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J. 2009;11(4):682–92.PubMedCentralCrossRefPubMed

22.

Lin S-L, Chang DC, Chang-Lin S, Lin C-H, Wu DT, Chen DT, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA. 2008;14(10):2115–24.PubMedCentralCrossRefPubMed

23.

Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4–Sox2–Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem. 2012;287(39):32800–24.PubMedCentralCrossRefPubMed

24.

Qian N-S, Liu W-H, Lv W-P, Xiang X, Su M, Raut V, et al. Upregulated MicroRNA-92b regulates the differentiation and proliferation of EpCAM-positive fetal liver cells by targeting C/EBPß. PLoS One. 2013;8(8):e68004.PubMedCentralCrossRefPubMed

25.

Qi J, Yu J-Y, Shcherbata HR, Mathieu J, Wang AJ, Seal S, et al. microRNAs regulate human embryonic stem cell division. Cell Cycle (Georgetown, Tex). 2009;8(22):3729.

26.

Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology. 2009;50(1):113–21.CrossRefPubMed

27.

Li W, Xie L, He X, Li J, Tu K, Wei L, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer. 2008;123(7):1616–22.CrossRefPubMed

28.

Xia H, Ooi LLP, Hui KM. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One. 2012;7(9):e44206.PubMedCentralCrossRefPubMed

29.

Wong CCL, Wong CM, Tung EKK, Au SLK, Lee JMF, Poon RTP, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011;140(1):322–31.CrossRefPubMed

30.

Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, et al. MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol. 2012;84(3):320–30.CrossRefPubMed

31.

Nakanishi Y, Seno H, Fukuoka A, Ueo T, Yamaga Y, Maruno T, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet. 2013;45(1):98–103.CrossRefPubMed

32.

Jangravi Z, Alikhani M, Arefnezhad B, Sharifi Tabar M, Taleahmad S, Karamzadeh R, et al. A fresh look at the male-specific region of the human Y chromosome. J Proteome Res. 2012;12(1):6–22.

33.

Eglitis MA, Mezey É. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci. 1997;94(8):4080–5.PubMedCentralCrossRefPubMed

Titel: RETRACTED ARTICLE: Profiling of differentially expressed microRNAs (miRNAs) during differentiation of rat hepatic oval cells (HOCs) into hepatocellular carcinoma (HCC) cells
verfasst von: R. H. Xu
L. Y. Zheng
D. L. He
J. Meng
L. P. Xia
X. B. Hao
Z. Z. Zhang
Publikationsdatum: 01.03.2015
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 3/2015
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-014-1218-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

RETRACTED ARTICLE: Profiling of differentially expressed microRNAs (miRNAs) during differentiation of rat hepatic oval cells (HOCs) into hepatocellular carcinoma (HCC) cells

Abstract

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Running away from side effects: physical exercise as a complementary intervention for breast cancer patients

Multidisciplinary cancer care may impact on the postoperative mortality and survival of patients with oesophageal and oesophagogastric junction cancer: a retrospective cohort study

Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics

Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies

Appendiceal carcinoid tumor in children: implications for less radical surgery?

Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie